Literature DB >> 15025151

Effects of ketanserin on hypergranulation tissue formation, infection, and healing of equine lower limb wounds.

Marc Engelen1, Béatrice Besche, Marie-Paul Lefay, Jonathan Hare, Kathleen Vlaminck.   

Abstract

The objective of this multicentre, randomized, controlled field study was to determine the efficacy of ketanserin gel in preventing exuberant granulation tissue formation (hypergranulation) and infection in equine lower limb wounds. Horses and ponies (n = 481) with naturally occurring wounds were randomized to either topical treatment with ketanserin gel (n = 242) or a positive control (Belgium, Germany: ethacridin lactate solution, n = 120; France, United Kingdom: malic, benzoic, and salicylic acid [MBS] cream, n = 119). Treatment continued until the wound healed (success), formed hypergranulation tissue (failure), or became infected (failure). Treatment was terminated after 6 months in all remaining animals. Ketanserin was successful in 88% of cases. Wounds treated with ketanserin were 2 and 5 times more likely to heal successfully than were those treated with MBS or ethacridin lactate, respectively. Ketanserin gel is thus more effective than these standard treatments in preventing hypergranulation tissue and infection of equine lower limb wounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025151      PMCID: PMC548604     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  20 in total

1.  Effect of serotonin on murine macrophages: suppression of Ia expression by serotonin and its reversal by 5-HT2 serotonergic receptor antagonists.

Authors:  E M Sternberg; J Trial; C W Parker
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

2.  A study to assess the effects of a new Betadine cream formulation compared to a standard topical treatment regimen for burns.

Authors:  M de Kock; A E van der Merwe
Journal:  Burns Incl Therm Inj       Date:  1987-02

3.  Serotonin, histamine, and norepinephrine mediation of endothelial and vascular smooth muscle cell movement.

Authors:  D Bottaro; D Shepro; S Peterson; H B Hechtman
Journal:  Am J Physiol       Date:  1985-03

4.  Preliminary observations on expression of transforming growth factors beta1 and beta3 in equine full-thickness skin wounds healing normally or with exuberant granulation tissue.

Authors:  Christine L Theoret; Spencer M Barber; Terence N Moyana; John R Gordon
Journal:  Vet Surg       Date:  2002 May-Jun       Impact factor: 1.495

5.  Temporal localization of immunoreactive transforming growth factor beta1 in normal equine skin and in full-thickness dermal wounds.

Authors:  Christine L Theoret; Spencer M Barber; John R Gordon
Journal:  Vet Surg       Date:  2002 May-Jun       Impact factor: 1.495

6.  Use of topical ketanserin in the treatment of skin ulcers: a double-blind study.

Authors:  P A Janssen; H Janssen; G Cauwenbergh; P De Doncker; K De Beule; P Lewi; H F Tytgat; C M Lapière
Journal:  J Am Acad Dermatol       Date:  1989-07       Impact factor: 11.527

7.  The effect of equine recombinant growth hormone on second intention wound healing in horses.

Authors:  Andrew J Dart; Lucile Cries; Leo B Jeffcott; David R Hodgson; Reuben J Rose
Journal:  Vet Surg       Date:  2002 Jul-Aug       Impact factor: 1.495

8.  Effects of 25% propylene glycol hydrogel (Solugel) on second intention wound healing in horses.

Authors:  Andrew J Dart; Lucile Cries; Leo B Jeffcott; David R Hodgson; Reuben J Rose
Journal:  Vet Surg       Date:  2002 Jul-Aug       Impact factor: 1.495

9.  Effect of wound location and the use of topical collagen gel on exuberant granulation tissue formation and wound healing in the horse and pony.

Authors:  A L Bertone; K E Sullins; T S Stashak; R W Norrdin
Journal:  Am J Vet Res       Date:  1985-07       Impact factor: 1.156

10.  Double-blind placebo-controlled study with topical 2% ketanserin ointment in the treatment of venous ulcers.

Authors:  P Roelens
Journal:  Dermatologica       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.